David Foehr Sells 4,560 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 4,560 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total value of $81,168.00. Following the sale, the vice president directly owned 17,550 shares in the company, valued at $312,390. This trade represents a 20.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

David Foehr also recently made the following trade(s):

• On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The stock was sold at an average price of $19.98, for a total value of $15,604.38.
• On Monday, February 23rd, David Foehr sold 569 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total value of $11,260.51.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $20.00, for a total transaction of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $22.60, for a total transaction of $125,565.60.

CeriBell Stock Down 0.3%

Shares of CeriBell stock opened at $17.83 on Friday. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.33. The firm’s 50 day moving average price is $20.77 and its 200-day moving average price is $16.46. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The company has a market cap of $671.12 million, a P/E ratio of -12.13 and a beta of 1.12.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. The firm had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. On average, sell-side analysts predict that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on CBLL shares. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, BTIG Research reiterated a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Institutional Investors Weigh In On CeriBell

Several large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in shares of CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after acquiring an additional 854 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in CeriBell by 97.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of CeriBell by 1.7% during the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after buying an additional 1,393 shares in the last quarter. Finally, Royal Bank of Canada raised its position in shares of CeriBell by 10.8% in the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock valued at $342,000 after buying an additional 1,514 shares during the last quarter.

Key Headlines Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Quarterly results beat expectations: CeriBell reported a narrower-than-expected loss (EPS -$0.36 vs. -$0.43 est.) and revenue topped estimates, which is a constructive fundamental data point for future guidance and valuation. MarketBeat CBLL
• Positive Sentiment: Analyst backing remains favorable: multiple firms (Canaccord, TD Cowen, BTIG) maintain Buy/Overweight stances and some have raised targets (Canaccord to $30), supporting medium-term upside relative to current levels. MarketBeat Analyst Coverage
• Neutral Sentiment: Short-interest report shows an apparent increase but the published data contains anomalies (0 shares / NaN increase and 0.0 days-to-cover), so there’s no reliable signal of a true rise in short activity at this time.
• Negative Sentiment: CEO sale: CEO Xingjuan Chao sold 39,000 shares (~$680,550 at ~$17.45), reducing his stake by ~5.2% — a large insider disposition that can be perceived negatively by the market. SEC Filing – CEO Sale
• Negative Sentiment: Other senior insider sales: CTO Raymond Woo (8,087 shares, ~$147.6k), VP David Foehr (4,560 shares, ~$81.2k) and Director Rebecca Robertson (827 shares, ~$14.7k) all sold shares in early March; multiple concurrent sales by senior execs amplify negative perception. SEC Filing – CTO Sale SEC Filing – VP Sale InsiderTrades – Director Sale

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.